Moody Aldrich Partners LLC Reduces Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Moody Aldrich Partners LLC trimmed its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 1.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 60,644 shares of the company’s stock after selling 1,107 shares during the period. Moody Aldrich Partners LLC owned 0.13% of Axsome Therapeutics worth $5,450,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. purchased a new position in Axsome Therapeutics during the 2nd quarter valued at about $27,000. EntryPoint Capital LLC purchased a new position in Axsome Therapeutics during the 1st quarter valued at about $35,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Axsome Therapeutics during the 2nd quarter valued at about $47,000. Russell Investments Group Ltd. raised its holdings in Axsome Therapeutics by 5,550.0% in the first quarter. Russell Investments Group Ltd. now owns 791 shares of the company’s stock worth $63,000 after buying an additional 777 shares during the last quarter. Finally, Covestor Ltd raised its holdings in Axsome Therapeutics by 54,750.0% in the first quarter. Covestor Ltd now owns 1,097 shares of the company’s stock worth $88,000 after buying an additional 1,095 shares during the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

AXSM has been the subject of several recent analyst reports. Bank of America raised shares of Axsome Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $95.00 to $106.00 in a report on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and set a $130.00 target price on shares of Axsome Therapeutics in a research report on Thursday, September 5th. StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 1st. Cantor Fitzgerald restated an “overweight” rating and set a $107.00 target price on shares of Axsome Therapeutics in a research report on Monday, September 16th. Finally, HC Wainwright restated a “buy” rating and set a $180.00 target price on shares of Axsome Therapeutics in a research report on Thursday, September 5th. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Axsome Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $124.64.

Insider Activity at Axsome Therapeutics

In related news, COO Mark L. Jacobson sold 47,739 shares of the stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $84.26, for a total value of $4,022,488.14. Following the transaction, the chief operating officer now owns 5,783 shares in the company, valued at approximately $487,275.58. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Mark E. Saad sold 11,016 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the sale, the director now owns 10,002 shares of the company’s stock, valued at $913,282.62. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Mark L. Jacobson sold 47,739 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $84.26, for a total transaction of $4,022,488.14. Following the sale, the chief operating officer now directly owns 5,783 shares in the company, valued at $487,275.58. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 22.40% of the stock is currently owned by insiders.

Axsome Therapeutics Trading Down 1.6 %

Shares of NASDAQ AXSM traded down $1.48 during mid-day trading on Thursday, reaching $90.84. The company had a trading volume of 131,399 shares, compared to its average volume of 625,439. The business’s 50-day moving average is $89.95 and its 200-day moving average is $81.90. The company has a current ratio of 2.48, a quick ratio of 2.40 and a debt-to-equity ratio of 1.77. The stock has a market cap of $4.31 billion, a price-to-earnings ratio of -14.47 and a beta of 1.26. Axsome Therapeutics, Inc. has a 52 week low of $55.02 and a 52 week high of $98.40.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Monday, August 5th. The company reported ($1.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.30) by $0.06. The company had revenue of $87.17 million for the quarter, compared to analysts’ expectations of $84.53 million. Axsome Therapeutics had a negative net margin of 105.85% and a negative return on equity of 117.46%. Equities analysts expect that Axsome Therapeutics, Inc. will post -4.73 earnings per share for the current year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.